Matthäus Willeit

5PUBLICATIONS
8CO-AUTHORS
Pharmaceutical delivery technologiesNeurology and neuromuscular diseasesToxicology (incl. clinical toxicology)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 14, 2026
Continuous infusion [<sup>11</sup>C]-(+)-PHNO PET for measuring dopamine D<sub>2/3</sub> receptor availability and amphetamine effects across the brain: Feasibility and test-retest reliability.

|Nov 20, 2024
The dopaminergic basis of negative symptoms in schizophrenia: an addendum.

Ana Weidenauer, Irena Dajic, Nicole Praschak-Rieder

|Aug 13, 2024
Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation.

Ana Weidenauer, Ulrich Sauerzopf, Martin Bauer

|Mar 29, 2024
The relationship between prefrontal cortex gray matter volume and subcortical dopamine release - an addendum.

Matthäus Willeit, Ulrich Sauerzopf, Nicole Praschak-Rieder

|Jan 28, 2022
Tricyclic antipsychotics and antidepressants can inhibit α5-containing GABA<sub>A</sub> receptors by two distinct mechanisms.

Konstantina Bampali, Filip Koniuszewski, Luca L Silva

Pageof 1

Frequent Collaborators

3 joint publications

Ana Weidenauer

1 joint publications

Konstantina Bampali

1 joint publications

Filip Koniuszewski

1 joint publications

Luca L Silva